| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine [M. A. M.] and Surgery [H. K. L., E. G., S. K. N.] and Center for Genetic and Cellular Therapies [M. A. M., H. K. L., E. G., S. K. N.], Duke University Medical Center, Durham, North Carolina 27710; and Immunex Corporation, Seattle, Washington 98101 [E. T.]
Dendritic cells (DCs), matured by CD40-ligand (CD40L), undergo marked changes in their ability to process and present antigen, resulting in augmented lymphocyte stimulatory activity. We demonstrate that the form of the tumor antigen (peptide or genetic material) used to load the DCs dictates the required sequence of antigen loading and maturation for antitumor immunotherapy. Optimal stimulation of carcinoembryonic antigen (CEA)-specific CTLs by peptide-loaded DCs occurs when DCs from cancer patients are matured with CD40L before exposure to CEA peptide, whereas optimal stimulation by RNA-transfected DCs occurs when the DCs are loaded with CEA RNA before maturation with CD40L.
1 Supported in part by NIH Grant R01-CA64946.
2 To whom requests for reprints should be addressed, at Duke University Medical Center, Box 2606, MSRB Room 401, Durham, NC 27710.
Received 4/ 3/98. Accepted 6/ 1/98.
This article has been cited by other articles:
|
|
 |
|
  L. J. Young, N. S. Wilson, P. Schnorrer, A. Mount, R. J. Lundie, N. L. La Gruta, B. S. Crabb, G. T. Belz, W. R. Heath, and J. A. Villadangos Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens PNAS, November 6, 2007; 104(45): 17753 - 17758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kornbluth and G. W. Stone Immunostimulatory combinations: designing the next generation of vaccine adjuvants J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. French, B. Huard, M. Wysocka, R. Shane, E. Contassot, J.-F. Arrighi, V. Piguet, S. Calderara, and A. H. Rook Impaired CD40L signaling is a cause of defective IL-12 and TNF-{alpha} production in Sezary syndrome: circumvention by hexameric soluble CD40L Blood, January 1, 2005; 105(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Watanabe, H. Kagamu, H. Yoshizawa, N. Fujita, H. Tanaka, J. Tanaka, and F. Gejyo The Duration of Signaling through CD40 Directs Biological Ability of Dendritic Cells to Induce Antitumor Immunity J. Immunol., December 1, 2003; 171(11): 5828 - 5836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nair, C. McLaughlin, A. Weizer, Z. Su, D. Boczkowski, J. Dannull, J. Vieweg, and E. Gilboa Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation J. Immunol., December 1, 2003; 171(11): 6275 - 6282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Samady, E. Costigliola, L. MacCormac, Y. McGrath, S. Cleverley, C. E. Lilley, J. Smith, D. S. Latchman, B. Chain, and R. S. Coffin Deletion of the Virion Host Shutoff Protein (vhs) from Herpes Simplex Virus (HSV) Relieves the Viral Block to Dendritic Cell Activation: Potential of vhs- HSV Vectors for Dendritic Cell-Mediated Immunotherapy J. Virol., March 15, 2003; 77(6): 3768 - 3776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Richards, N. M. Ampel, and D. F. Lake Reversal of Coccidioidal Anergy In Vitro by Dendritic Cells from Patients with Disseminated Coccidioidomycosis J. Immunol., August 15, 2002; 169(4): 2020 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ni, J. Capodici, G. Cannon, D. Communi, J.-M. Boeynaems, K. Kariko, and D. Weissman Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-alpha Secretion and Signaling through a Nucleotide Receptor J. Biol. Chem., April 5, 2002; 277(15): 12689 - 12696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Timmerman, D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood, March 1, 2002; 99(5): 1517 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Termeer, H. Johannsen, T. Braun, A. Renkl, T. Ahrens, R. W. Denfeld, M. B. Lappin, J. M. Weiss, and J. C. Simon The role of CD44 during CD40 ligand-induced dendritic cell clustering and maturation J. Leukoc. Biol., November 1, 2001; 70(5): 715 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Faries, I. Bedrosian, S. Xu, G. Koski, J. G. Roros, M. A. Moise, H. Q. Nguyen, F. H. C. Engels, P. A. Cohen, and B. J. Czerniecki Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development Blood, October 15, 2001; 98(8): 2489 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. F. I. Van Tendeloo, P. Ponsaerts, F. Lardon, G. Nijs, M. Lenjou, C. Van Broeckhoven, D. R. Van Bockstaele, and Z. N. Berneman Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells Blood, July 1, 2001; 98(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhu, H. Terasawa, J. Gulley, D. Panicali, P. Arlen, J. Schlom, and K. Y. Tsang Enhanced Activation of Human T Cells via Avipox Vector-mediated Hyperexpression of a Triad of Costimulatory Molecules in Human Dendritic Cells Cancer Res., May 1, 2001; 61(9): 3725 - 3734. [Abstract] [Full Text]
|
|
|
|
|
|
A. Heiser, M. A. Maurice, D. R. Yancey, D. M. Coleman, P. Dahm, and J. Vieweg Human Dendritic Cells Transfected with Renal Tumor RNA Stimulate Polyclonal T-Cell Responses against Antigens Expressed by Primaryand Metastatic Tumors Cancer Res., April 1, 2001; 61(8): 3388 - 3393. [Abstract] [Full Text]
|
|
|
|
|
|
A. Heiser, M. A. Maurice, D. R. Yancey, N. Z. Wu, P. Dahm, S. K. Pruitt, D. Boczkowski, S. K. Nair, M. S. Ballo, E. Gilboa, et al. Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA J. Immunol., March 1, 2001; 166(5): 2953 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Candido, K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents Cancer Res., January 1, 2001; 61(1): 228 - 236. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Lambert, G. R. Gibson, M. Maloney, B. Durell, R. J. Noelle, and R. J. Barth Jr. Intranodal Immunization with Tumor Lysate-pulsed Dendritic Cells Enhances Protective Antitumor Immunity Cancer Res., January 1, 2001; 61(2): 641 - 646. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. K. Lyerly, T. Clay, and M. A. Morse Optimizing Dendritic Cell Function by Genetic Modification J Natl Cancer Inst, August 2, 2000; 92(15): 1198 - 1199. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hodge, A. N. Rad, D. W. Grosenbach, H. Sabzevari, A. G. Yafal, L. Gritz, and J. Schlom Enhanced Activation of T Cells by Dendritic Cells Engineered to Hyperexpress a Triad of Costimulatory Molecules J Natl Cancer Inst, August 2, 2000; 92(15): 1228 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kikuchi, M. A. S. Moore, and R. G. Crystal Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors Blood, July 1, 2000; 96(1): 91 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Samten, E. K. Thomas, J. Gong, and P. F. Barnes Depressed CD40 Ligand Expression Contributes to Reduced Gamma Interferon Production in Human Tuberculosis Infect. Immun., May 1, 2000; 68(5): 3002 - 3006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. J. Bullock, T. A. Colella, and V. H. Engelhard The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice J. Immunol., March 1, 2000; 164(5): 2354 - 2361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Kiertscher, J. Luo, S. M. Dubinett, and M. D. Roth Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells J. Immunol., February 1, 2000; 164(3): 1269 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Morse, Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, S. Nair, J. Schlom, M.-E. Ryback, and H. K. Lyerly A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen Clin. Cancer Res., June 1, 1999; 5(6): 1331 - 1338. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
